EPCAM and ocular melanoma: OM is a recombinant fusion protein that contains an anti-epithelial cell adhesion molecule antibody and Pseudomonas exotoxin A. Indeed OM also received an FDA fast-track designation in August 2018 and a priority review in February 2021 (36).